From single‑cell screening to molecular characterization.

As the home of Sphere Bio and Fluidity One‑M, Fluidic Sciences delivers an end‑to‑end portfolio for complex biology. Move seamlessly from multiplex single‑cell screening to in‑solution biophysics—reducing assumptions and accelerating confident decisions.

Abzena's new platform integrates Cyto-Mine® to reduce timelines, boost productivity, and ensure monoclonality—at scale.

Traditional screening misses more than it finds. Screen up to 40 million cells in a day—without compromising viability. Don’t let your best cell go undiscovered.

Make your decisions earlier and with precision. You can screen millions of cells in 4-6 hours—gently, accurately, and with monoclonality assurance. Hit your milestones sooner.

Achieve high-throughput screening, verified monoclonality, and viable single-cell dispensing. Hit your milestones sooner.

From CAR-T to rare primary cells, screen more candidates with greater precision—without compromising viability.

Integration will expand applications across antibody discovery, cell line development, cell therapy, and complex protein interaction analysis